Article

Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-alpha in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 1

JW Goethe University Hospital, Frankfurt, Germany.
Gastroenterology (Impact Factor: 13.93). 10/2010; 139(4):1257-66. DOI: 10.1053/j.gastro.2010.06.066
Source: PubMed

ABSTRACT The current standard of care for patients with chronic hepatitis C virus (HCV) genotype 1 is once-weekly pegylated interferon-α (Peg-IFNα) plus daily ribavirin for 48 weeks. We evaluated the efficacy/safety of albinterferon alfa-2b (albIFN), a novel, long-acting, genetic fusion polypeptide of albumin and IFNα-2b.
In the phase 3 ACHIEVE-1 trial, 1331 patients were assigned equally to 3 open-label, 48-week treatment groups: Peg-IFNα-2a 180 μg every week, or albIFN 900 or 1200 μg every 2 weeks administered subcutaneously, with weight-based oral ribavirin 1000-1200 mg/day. During the study, the data monitoring committee recommended dose modification for all patients receiving albIFN 1200 μg to 900 μg because of increased pulmonary adverse events (AEs) in the 1200-μg arms of both ACHIEVE studies. Main outcome measure was sustained virologic response (SVR; undetectable serum HCV RNA at week 72).
Intention-to-treat SVR rates were 51.0% (225/441), 48.2% (213/442), and 47.3% (208/440) with Peg-IFNα-2a, and albIFN 900 and 1200 μg, respectively. The primary objective of showing noninferiority of albIFN 900 μg (P < .001) and 1200 μg (P = .003) vs Peg-IFNα-2a for SVR was achieved. Multivariate modeling indicated consistency of treatment effect across subgroups. Serious/severe AE rates were 23.1%, 24.0%, 28.2%; treatment discontinuation rates because of AEs were 4.1%, 10.4%, 10.0%; discontinuation rates because of respiratory AEs were 0%, 0.9%, 1.6%; with Peg-IFNα-2a, and albIFN 900 and 1200 μg, respectively. Hematologic abnormality rates were comparable across the Peg-IFNα-2a and albIFN 900-μg groups.
albIFN 900 μg every 2 weeks showed comparable efficacy, with similar serious/severe AE rates, although with a higher discontinuation rate, vs Peg-IFNα-2a in patients with chronic HCV genotype 1.

0 Followers
 · 
136 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The effect of different formulations of interferon on therapeutic response in patients coinfected with HIV and HCV is unclear. In this study, the safety, tolerability, viral kinetics (VK) modeling and host responses among HIV/HCV coinfected patients treated with pegylated-IFN or albinterferon alfa-2b (AlbIFN) with weight-based ribavirin were compared. Three trials treated 57 HIV/HCV coinfected genotype-1 patients with PegIFN alfa-2b (1.5 µg/kg/week) (n = 30), PegIFN alfa-2a (180 µg/week) (n = 10), and AlbIFN (900 µg/q2week) (n = 17) in combination with weight-based ribavirin (RBV). HCV RNA, safety labs, and interferon stimulated gene expression (ISG) was evaluated. Adverse events were documented at all study visits. HCV viral kinetics using a full pharmacokinetic/pharmacodynamic model was also evaluated. Baseline patient characteristics were similar across the three studies. All three formulations exhibited comparable safety and tolerability profiles and efficacy. VK/PK/PD parameters for all three studies as measured by mean efficiency and rate of infected cell loss were similar between the three groups. Host responses (ISG expression and immune activation markers) were similar among the three groups. All three regimens induced significant ISG at week 4 (P < 0.05) and ISG expression strongly correlated with therapeutic response (r = 0.65; P < 0.01). In summary, a comprehensive analysis of responses to three different interferon formulations in HIV/HCV coinfected patients demonstrated similar effects. Notably, interferon-based therapy results in a blunted host response followed by modest antiviral effect in HIV/HCV coinfected patients. This suggests that future treatment options that do not rely on host immune responses such as direct antiviral agents would be particularly beneficial in these difficult to treat patients. J. Med. Virol. © 2013 Wiley Periodicals, Inc.
    Journal of Medical Virology 02/2014; 86(2). DOI:10.1002/jmv.23773 · 2.22 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Not Available
    Millimeter Wave and Far-Infrared Technology, 1989. ICMWFT '89. International Conference on; 02/1989
  • [Show abstract] [Hide abstract]
    ABSTRACT: Via formation using photosensitive polymer technology reduces process cost and is hence of great interest in electronics packaging substrate fabrication. However, to overcome process complexity issues and to facilitate low-cost manufacturing, process optimization and control are required. In this paper, a modeling approach for via formation in MCM dielectric layers composed of photosensitive benzocyclobutene (BCB) is presented. A series of designed experiments are used to characterize the via formation work-cell (which consists of the spin coat, soft bake, expose, develop, cure, and plasma de-scum unit process steps). Sequential neural network process models are then constructed to characterize entire via formation process. In the sequential scheme, each work-cell sub-process is modeled individually, and each sub-process model is linked to previous sub-process outputs and subsequent sub-process inputs. This modeling scheme is compared with two other modeling approaches to evaluate model prediction capability. The sequential method shows superior prediction capability. This modeling structure will be useful for feedback and feed-forward process control, and it will eventually be used for development of supervisory process control scheme
    Advanced Packaging Materials, 1998. Proceedings. 1998 4th International Symposium on; 04/1998